A carregar...
Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
Background: In the pivotal phase III 2-year ADVANCE study, subcutaneous peginterferon beta-1a 125 mcg every 2 weeks demonstrated significant improvements in clinical outcomes, including disability endpoints, in patients with relapsing–remitting multiple sclerosis (RRMS). Here, we aim to further eval...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2017-01-01
|
| Colecção: | Therapeutic Advances in Neurological Disorders |
| Acesso em linha: | https://doi.org/10.1177/1756285616676065 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|